Last reviewed 2026-05-15 · How we verify

Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge

University of Wisconsin, Madison · FDA-approved active Small molecule Quality 17/100

Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge is a Nicotine replacement therapy (NRT) Small molecule drug developed by University of Wisconsin, Madison. It is currently FDA-approved. Also known as: Cessation Phase Combination NRT.

The combination of Cessation Phase Nicotine Patch and Nicotine Mini-Lozenge is a smoking cessation therapy developed by the University of Wisconsin, Madison. This dual-therapy approach aims to reduce nicotine withdrawal symptoms and cravings by providing a steady dose of nicotine through the patch and additional doses via lozenges as needed. The treatment is designed to help smokers gradually reduce their dependence on cigarettes. While there is no FDA label, the therapy has shown promise in clinical trials and is being evaluated for broader use. Common side effects include nausea, headache, and dizziness, which are generally mild to moderate in severity.

At a glance

Generic name	Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge
Also known as	Cessation Phase Combination NRT
Sponsor	University of Wisconsin, Madison
Drug class	Nicotine replacement therapy (NRT)
Target	Nicotinic acetylcholine receptors
Modality	Small molecule
Therapeutic area	Hematology
Phase	FDA-approved

Approved indications

No approved indications tracked.

Pipeline indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge CI brief — competitive landscape report
Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge updates RSS · CI watch RSS
University of Wisconsin, Madison portfolio CI

Frequently asked questions about Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge

What is Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge?

Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge is a Nicotine replacement therapy (NRT) drug developed by University of Wisconsin, Madison.

Who makes Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge?

Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge is developed and marketed by University of Wisconsin, Madison (see full University of Wisconsin, Madison pipeline at /company/university-of-wisconsin-madison).

Is Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge also known as anything else?

Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge is also known as Cessation Phase Combination NRT.

What drug class is Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge in?

Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge belongs to the Nicotine replacement therapy (NRT) class. See all Nicotine replacement therapy (NRT) drugs at /class/nicotine-replacement-therapy-nrt.

What development phase is Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge in?

Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge is FDA-approved (marketed).

What does Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge target?

Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge targets Nicotinic acetylcholine receptors and is a Nicotine replacement therapy (NRT).

Drug class: All Nicotine replacement therapy (NRT) drugs
Target: All drugs targeting Nicotinic acetylcholine receptors
Manufacturer: University of Wisconsin, Madison — full pipeline
Therapeutic area: All drugs in Hematology
Also known as: Cessation Phase Combination NRT
Compare: Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge vs similar drugs
Pricing: Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge cost, discount & access